Meeting report: targeting the kinome--20 years of tyrosine kinase inhibitor research in Basel.
With basic and pharmaceutical researchers, chemists, pharmacologists, and clinicians, the Targeting the Kinome meeting brought together a tremendous group of scientists to discuss the past, present, and future of protein kinase research, with a special emphasis on cancer therapy development. The topics ranged from the kinases themselves as drug targets through the interactions that the actions of these enzymes promote, to the physiological and pathological processes they regulate. Attendees gained insight into drug development, as well as increased understanding of how normal cellular processes are subverted during oncogenesis, which may lead to new targets for intervention.
Bozulic
Lana
L
Friedrich Miescher Institute for Biomedical Research, Basel, Switzerland.
Morin
Pier
P
Hunter
Tony
T
Hemmings
Brian A
BA
D000818:Animals; D016503:Drug Delivery Systems; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000209:etiology; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases